Osteoporosis International

, Volume 22, Issue 6, pp 1659–1667

How strontium ranelate, via opposite effects on bone resorption and formation, prevents osteoporosis

Authors

    • Laboratory of Osteoblast Biology and PathologyINSERM, U606
    • University Paris Diderot, UMR606
    • Hôpital Lariboisière, INSERM U606
  • D. Felsenberg
    • Centre for Muscle and Bone ResearchCharité Campus Benjamin Franklin
  • M. L. Brandi
    • Department of Internal MedicineUniversity of Florence
Review

DOI: 10.1007/s00198-010-1369-0

Cite this article as:
Marie, P.J., Felsenberg, D. & Brandi, M.L. Osteoporos Int (2011) 22: 1659. doi:10.1007/s00198-010-1369-0

Abstract

Oestrogen deficiency increases the rate of bone remodelling which, in association with a negative remodelling balance (resorption exceeding formation), results in impaired bone architecture, mass and strength. Current anti-osteoporotic drugs act on bone remodelling by inhibiting bone resorption or by promoting its formation. An alternative therapeutic approach is based on the concept of inducing opposite effects on bone resorption and formation. One therapeutic agent, strontium ranelate, was shown to induce opposite effects on bone resorption and formation in pre-clinical studies and to reduce fracture risk in postmenopausal osteoporotic patients. How strontium ranelate acts to improve bone strength in humans remains a matter of debate, however. This review of the most recent pre-clinical and clinical studies is a critical analysis of strontium ranelate’s action on bone resorption and formation and how it increases bone mass, microarchitecture and strength in postmenopausal osteoporotic women.

Keywords

Bone cellsOsteoporosisStrontium ranelate

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2010